萘替芬酮康唑乳膏治疗体股癣疗效观察

目的评价萘替芬酮康唑乳膏(必亮乳膏)治疗体股癣的疗效。方法100例患者随机分为治疗组和对照组各50例,分别外用萘替芬酮康唑乳膏、硝酸咪康唑乳膏,均早晚各1次,疗程4周。在治疗的第2,4周和停药1周时观察记录患者皮损变化、不良反应及皮损处皮屑真菌镜检,并评价疗效。结果治疗的第4周和停药1周时,治疗组疗效明显优于对照组(P(0.05),治疗组和对照组局部不良反应发生率分别为6.00%,4.00%,症状较轻,均能坚持治疗。结论外用萘替芬酮康唑乳膏(必亮乳膏)治疗体股癣疗效较好,不良反应发生率低。     

复方地肤子洗剂联合萘替芬酮康唑乳膏治疗足癣疗效观察1秦建平,徐杰,黄丽蓉,杨登科

目的 观察我院自制复方地肤子洗剂联合萘替芬酮康唑乳膏治疗足癣的临床疗效。方法 将2019年5月至2019年10月皮肤科门诊接诊确诊为足癣符合纳入标准的患者61例,随机分为2组,对照组单纯外用萘替芬酮康唑乳膏(必亮,重庆华邦制药有限公司),2次/d,每次适量;治疗组在对照组的基础上加用复方地肤子洗剂外泡足,每晚一次。结果 治疗组30例,总有效率90%;对照组31例,总有效率77.4%。结论 自制复方地肤子洗剂联合萘替芬酮康唑乳膏治疗足癣疗效优于单纯外用萘替芬酮康唑乳膏。     

窄谱中波紫外线联合萘替芬酮康唑乳膏治疗股癣49例

目的观察窄谱中波紫外线(NB-UVB)联合萘替芬酮康唑乳膏治疗股癣的临床疗效。方法将100患者随机分为两组,治疗组给予NB-UVB联合萘替芬酮康唑乳膏治疗,对照组单用萘替芬酮康唑乳膏,每周观测1次,治疗3周后判断疗效。结果两组真菌清除率各周比较均无统计学意义。治疗组有效率为91.8%,对照组有效率为85.1%,两组比较差异有统计学意义(P0.05)。两组均无明显不良反应。结论 NB-UVB联合萘替芬酮康唑乳膏治疗股癣疗效肯定,临床上值得应用。     

1％吡美莫司乳膏治疗40例面部脂溢性皮炎临床疗效观察

目的：观察1%吡美莫司乳膏治疗面部脂溢性皮炎的疗效.方法：80例面部脂溢性皮炎患者随机分成治疗组和对照组.治疗组予1%吡美莫司乳膏外用,对照组予5%氟芬那酸丁酯软膏外用,均每日2次,连续4周.结果：治疗组的总有效率为 90%,对照组的总有效率为67.5%,两组差异有统计学意义（P〈0.05）.结论：1%吡美莫司乳膏治疗面部脂溢性皮炎疗效好,副作用少.     

丁苯羟酸乳膏联合丁酸氢化可的松治疗面部脂溢性皮炎疗效观察

目的了解丁苯羟酸乳膏结合丁酸氢化可的松乳膏外用治疗面部脂溢性皮炎的疗效。方法将符合入选标准的135例面部脂溢性皮炎的患者随机分为两组。治疗组67例早晨外涂丁酸氢化可的松乳膏,晚上外涂丁苯羟酸乳膏,每日各1次,2周后仅以丁苯羟酸乳膏外涂,2次/d,共4周。对照组外涂丁酸氢化可的松乳膏,每日早晚各1次,共4周。治疗结束后比较两组疗效。结果治疗组的临床治愈率为30.77%,对照组为27.69%,差异无统计学意义(P>0.05)。复发率治疗组为18.46%,对照组为35.39%,两者比较差异有统计学意义(P<0.05)。治疗耐受性好且无严重不良反应发生。结论丁苯羟酸乳膏结合丁酸氢化可的松乳膏外用治疗面部脂溢性皮炎有着较好的临床疗效,是激素治疗的辅助剂。     

0.05%地奈德乳膏治疗三种常见皮肤病的疗效观察

目的评价0.05%地奈德乳膏治疗特应性皮炎、脂溢性皮炎及寻常性银屑病的临床疗效及安全性。方法采用开放式研究。分别应用0.05%地奈德、1%丁酸氢化可的松及0.1%糠酸莫米松乳膏治疗特应性皮炎、脂溢性皮炎及寻常性银屑病。对患者治疗前后红斑、糜烂、浸润、丘疹、渗出/结痂、瘙痒及皮损面积的总积分进行评价。结果治疗2周后,地奈德组的临床疗效明显优于丁酸氢化可的松组,差异有显著性(P<0.05),两组均未见明显不良反应;地奈德组的疗效与糠酸莫米松组相当(P>0.05),但后者有1例出现瘙痒,1例出现红斑加重。结论应用0.05%地奈德乳膏治疗特应性皮炎、脂溢性皮炎及寻常性银屑病疗效可靠,临床使用安全。     

曲安奈德益康唑乳膏治疗脂溢性皮炎78例临床观察

目的观察曲安奈德益康唑乳膏治疗微生物相关皮肤病脂溢性皮炎的临床疗效及安全性。方法治疗组78例脂益性皮炎患者，予早、晚各1次外用曲安奈德益康唑乳膏，并轻揉搓片刻，疗程4周。对照组80例予外搽皮炎平，用药方法及疗程同前。每周复诊时观察皮损情况。结果治疗组有效率89．3％，对照组为66．6％；治疗组出现不良反应3例，占3．8％，均予对症处理，与对照组（8例）比较差异有统计学意义（P〈0．05）。结论曲安奈德益康唑乳膏治疗脂溢性皮炎疗效确切，不良反应少。     

奈替芬酮康唑乳膏治疗马拉色菌毛囊炎123例疗效观察

目的观察萘替芬酮康唑乳膏治疗马拉色菌毛囊炎的临床疗效和安全性。方法将245例马拉色菌毛囊炎患者随机分为试验组和对照组:试验组采用萘替芬酮康唑乳膏外用,对照组采用酮康唑乳膏外用,均早晚各1次,疗程4周。结果试验组和对照组的有效率分别是81.30%和47.54%(P<0.01);试验组无不良反应出现。结论萘替芬酮康唑乳膏治疗马拉色菌毛囊炎的疗效优于酮康唑乳膏,且安全可靠。     

萘替芬酮康唑乳膏治疗花斑癣的疗效观察

目的观察萘替芬酮康唑乳膏治疗花斑癣的疗效。方法将63例患者随机分为治疗组和对照组,治疗组外用萘替芬酮康唑乳膏,对照组外用硝酸咪康唑乳膏,根据疗效指数和真菌镜检结果判定疗效。结果治疗组治疗2周及4周时的疗效(2周时为65.63%和4周时为96.88%)和治疗2周时真菌清除率(治疗组78.13%,对照组51.61%)均明显高于对照组(2周时为38.71%和4周时为80.65%),差异均有统计学意义(P0.05)。结论萘替芬酮康唑乳膏治疗花斑癣安全而有效。     

萘替芬酮康唑乳膏与两种中药制剂合用治疗角化过度型足癣临床观察

目的观察萘替芬酮康唑乳膏分别联合中药复方香莲外洗液、抗真菌颗粒剂治疗角化过度型足癣的临床疗效。方法将120例角化过度型足癣患者随机分为A组40例(萘替芬酮康唑乳膏外用联合温水外洗)、B组40例(萘替芬酮康唑乳膏外用联合中药抗真菌颗粒剂口服)和C组40例(萘替芬酮康唑乳膏联合中药复方香莲外洗液外用),观察3组患者的临床疗效和真菌学疗效。结果停药后2周时,A,B和C三组的痊愈率分别是34.21%,57.89%和82.50%,有效率分别是68.42%,89.47%和97.50%,真菌清除率分别是89.47%,92.11%和100.00%。C组和B组的痊愈率、有效率均明显高于A组(P均<0.05);C组的痊愈率明显高于B组(P<0.05),有效率则略高于B组,但两者相比无明显差异(P>0.05)。C组的真菌清除率明显高于A组(P<0.05);C组与B组、B组与A组的真菌清除率比较均无明显差异(P均>0.05)。结论萘替芬酮康唑乳膏分别与中药复方香莲外洗液、抗真菌颗粒剂联合治疗角化过度型足癣均取得较好的疗效和安全性。     

盐酸特比萘芬乳膏治疗面部脂溢性皮炎的临床疗效观察

目的评价盐酸特比萘芬乳膏外用治疗面部脂溢性皮炎的疗效与安全性。方法 78例面部脂溢性皮炎患者随机分成两组,试验组39例,接受盐酸特比萘芬乳膏外用治疗,每日2次;对照组39例,接受复方益康唑乳膏治疗,每日2次。两组患者疗程均为4周,每2周复诊1次,复诊时观察和记录疗效和不良反应,治疗结束1个月后对两组患者进行随访。结果治疗2、4周后,两组患者症状总积分均较治疗前明显下降,差异有统计学意义(P0.01)。治疗2周后,试验组和对照组总有效率分别为71.8%和76.9%;治疗4周后,试验组和对照组总有效率分别为79.5%和84.6%,组间差异均无统计学意义(P0.05)。此外,治疗4周后两组患者马拉色菌菌量均比治疗前明显减少,且试验组可检出马拉色菌菌量明显少于对照组。1个月后随访结果表明,试验组复发率为7.7%,显著低于对照组的43.8%。试验组和对照组不良反应发生率分别为10.3%和30.8%。结论外用盐酸特比萘芬乳膏与外用复方益康唑乳膏治疗面部脂溢性皮炎疗效均令人满意,但外用盐酸特比萘芬乳膏的复发率更低,且无糖皮质激素乳膏外用所致的不良反应。     

Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study

BACKGROUND: Recently, two placebo-controlled studies have shown that topical metronidazole was effective in the treatment of seborrheic dermatitis. OBJECTIVE: To compare the efficacy and safety of metronidazole 0.75% gel with that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis. METHODS: A total of 60 consecutive patients with facial seborrheic dermatitis were included. Patients were randomized into two groups. One group used ketoconazole 2% cream with metronidazole gel as vehicle; the other group used metronidazole 0.75% gel with ketoconazole cream as vehicle for a 4-week treatment period. Main outcome measures were change in clinical severity scores, patients' and investigator's global evaluation of improvement and frequency of side-effects. RESULTS: All the assessments were made by an investigator who was unaware of which group the patients were allocated to. Mean percentage decrease in clinical severity scores from baseline to last available visit was 63.4% (95% CI 57.7-69) and 54.4% (95% CI 47.9-61) in the ketoconazole- and metronidazole-treated patients, respectively (P = 0.31). Eighty-two per cent of patients in the ketoconazole group vs. 79% of patients in the metronidazole group rated their global improvement as significant or moderate (P > 0.05). No statistically significant difference in the frequency of side-effects was detected between the two groups. The results of this study need to be confirmed in further studies involving large numbers of patients. CONCLUSION: Our data demonstrated that metronidazole 0.75% gel had a comparable efficacy and safety profile with that of ketoconazole 2% cream in the treatment of facial seborrheic dermatitis.     

羌月乳膏治疗面部脂溢性皮炎的临床观察

目的探讨中药制剂羌月乳膏治疗面部脂溢性皮炎的有效性和安全性。方法将入选的120例面部脂溢性皮炎患者随机分为观察组60例(予羌月乳膏)和对照组60例(予丁苯羟酸软膏),连续局部用药4周。并在治疗结束后随访2周。结果治疗组有效率与对照组差异无统计学意义,在复发率和安全性方面治疗组优于对照组,差异有统计学意义。结论中药制剂羌月乳膏是治疗脂溢性皮炎的安全有效的外用药,而且复发率低,可作为治疗面部脂溢性皮炎的一线用药。     

类人胶原蛋白敷料治疗面部脂溢性皮炎疗效观察及对皮肤屏障功能的影响

目的探讨类人胶原蛋白敷料治疗面部脂溢性皮炎的疗效、安全性及其对皮肤屏障功能的影响。方法将20~50岁女性面部脂溢性皮炎患者67例随机入组,试验组患者外用酮康唑乳膏加类人胶原蛋白敷料,对照组患者单独外用酮康唑乳膏,两组患者均用药10 d,观察皮损变化并测定皮肤屏障功能相关指标。结果第2次随访时,试验组症状积分[(1.06±1.06)分]、经皮水分丢失量(transepidermal water loss,TEWL)[(11.99±5.84)g/(m2?h)]均低于对照组[(1.94±1.17)分、(16.17±8.47)g/(m2?h)],角质层含水量(40.20±11.69)高于对照组(34.13±10.86),差异均有统计学意义(P=0.002,0.024,0.033)。两组患者均未出现明显不良反应。结论类人胶原蛋白敷料治疗成年女性面部脂溢性皮炎,能改善皮肤屏障功能,减轻皮损,可以作为面部脂溢性皮炎的一个安全有效的辅助治疗手段。     

Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis

Seborrheic dermatitis traditionally has been treated with topical steroids. In current practice, however, antifungal agents such as ketoconazole often are used because Malassezia yeasts are thought to play a role in the disease pathogenesis. Ketoconazole gel 2% has been developed for the once-daily treatment of seborrheic dermatitis. This gel is almost invisible after application, unlike ketoconazole cream, and may offer advantages in patient acceptance and adherence to treatment. Three randomized, double-blinded, vehicle-controlled, multicenter, parallel-group phase 3 studies evaluated the efficacy and tolerability of ketoconazole gel 2% compared with a vehicle gel in more than 900 subjects with moderate to severe seborrheic dermatitis who applied treatment for 14 days and were followed for an additional 14 days. Two of these studies also compared a combination gel containing ketoconazole 2% and desonide 0.05%, each active gel individually, and a vehicle control. Subjects were considered effectively treated if the erythema and scaling as well as investigator global assessment (IGA) scores decreased to 0 (or 1 if the baseline score was > or =3) by day 28. Pooled data from these studies showed that the proportion of effectively treated subjects was significantly greater in the ketoconazole gel 2% treatment group compared with the vehicle group (P < .001). The comparison of the combination gel to its individual components revealed that the efficacy of ketoconazole alone was comparable to the combination gel as well as desonide gel alone for up to 2 weeks after the end of treatment. These data suggest that once-daily ketoconazole gel 2% is an effective treatment for seborrheic dermatitis and a viable alternative to the ketoconazole cream 2% formulation.     

Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream

A 71-year-old woman visited our clinic due to the presence of widespread scaly erythema on her face, scalp, and lower extremities. She was tentatively diagnosed as having seborrheic dermatitis but the symptoms were difficult to distinguish from psoriasis vulgaris. As a result, she was diagnosed as having sebopsoriasis. She was treated topically with an active vitamin D3 compound, 1a-24 (R)-dihydroxycholecalciferol D3 (tacalcitol) cream. She applied tacalcitol cream twice daily for 4 weeks, and her facial eruptions thus cleared up completely. No recurrence was observed for 2 months thereafter, even though the use of tacalcitol cream was stopped. To investigate whether or not tacalcitol cream is generally effective for the treatment of such seborrheic dermatitis-like eruptions, three more patients were treated with tacalcitol cream. All patients exhibited scaly erythematous macules on the face and/or scalp, and their eruptions improved rapidly with tacalcitol cream. Tacalcitol cream was thus found to be effective and useful for the treatment of both sebopsoriasis and even seborrheic dermatitis of the face and scalp.     

Randomized,open-labeled,non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis

BACKGROUND: Topical ketoconazole (KC) is considered a standard treatment for seborrheic dermatitis. In a placebo-controlled, double-blind clinical study, we demonstrated that antifungal ciclopiroxolamine (CIC) 1% cream was effective in mild to moderate facial seborrheic dermatitis. OBJECTIVES: We report here the results of a randomized, open-labeled clinical study comparing CIC 1% cream and KC 2% foaming gel in patients with mild to moderate facial seborrheic dermatitis, using a non-inferiority trial design. METHODS: Three hundred and three patients were enrolled, 154 patients in the CIC group and 149 patients in the KC group, and comprised the study population for intent-to-treat (ITT) analysis. The per protocol (PP) population comprised a total of 282 patients, 147 in the CIC group and 135 in the KC group. Patients were randomly allocated to apply either the CIC 1% cream twice a day for 28 days maximum (initial phase), followed by once a day for another 28 days (maintenance phase); or the KC 2% foaming gel twice a week at the initial phase, followed by once a week during the maintenance phase. Test lesions were defined as lesions localized to the nasolabial folds, alae nasi, and/or the eyebrows. The main efficacy parameter (endpoint) was the proportion of patients who presented a complete disappearance of both erythema and scaling on test lesions and pruritus on all lesions at the end of the initial phase (28 days or less). RESULTS: At baseline, both treatment groups were comparable in terms of demographic data and lesional status. At the end of the initial phase, responders were found to be non-inferior with CIC treatment compared with KC treatment in both study populations (ITT population: 37% CIC responders and 34% KC responders; in the PP population: 39 and 36% responders, respectively). The 95% confidence interval limit for differences were -7.99-13.56 in the ITT population, and -8.06-14.5 in the PP population. At the end of the maintenance phase, treatment response to CIC was greater than to KC in both ITT and PP populations (57 and 44% in both populations, respectively, p = 0.03). Local tolerance as well as global acceptability was better with CIC than with KC (p = 0.001, intergroup analysis). CONCLUSION: CIC 1% administered as a cream demonstrated to be non-inferior to KC 2% foaming gel in mild to moderate facial seborrheic dermatitis.